Zealand Pharma enters US partnership over pump system

Biotech company Zealand Pharma has gained access to an infusion pump from the US-based Deka, which will be used with the drug dasiglucagon for the treatment of severe low blood sugar. Zealand Pharma is also granted worldwide exclusive rights for the pump in combination with the drug.

Photo: Stine Bidstrup/ERH

Zealand Pharma and Deka Research & Development have partnered up to developed an infusion pump system, which will include the drug dasiglucagon, meant to treat patients with congenital hyperinsulinism (CHI), which is severe and persistent low blood sugar, Zealand Pharma reports in a press release.

Hyperinsulinism is a genetic disorder that causes improper levels of blood sugar due to abnormally high insulin amounts in the body.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs